Biotech firms Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio, which will develop gene-editing therapies. The new company raised $75m in a funding round led by Cormorant Asset Management and others, with the funds to be used to continue developing a lead therapy for liver disease. The company plans to build a broad pipeline of epigenetic editors that target hepatic and extrahepatic diseases.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
